Opendata, web and dolomites

HypoSkin SIGNED

Unique breakthrough ex vivo human skin model to predict efficacy and toxicity of subcutaneous drugs

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 HypoSkin project word cloud

Explore the words cloud of the HypoSkin project. It provides you a very rough idea of what is the project "HypoSkin" about.

animal    human    innovative    2024    accurate    standardized    containing    cagr    life    global    sme    predict    1b    reliably    causing    drug    center    700k    clinical    genoskin    paul    jobs    times    money    route    experiment    framework    inadequate    biological    vitro    vivo    payed    confirmed    disruptive    decrease    founded    reference    medical    alternative    110    secure    88    market    living    tissue    kit    subcutaneous    national    quality    home    innovation    administration    risks    skin    permits    companies    time    sabatier    injection    leads    device    biopsies    world    instrument    faster    french       security    2011    turnover    view    company    parenteral    worldwide    limits    cheaper    off    34    pilot    deepen    feasibility    improves    care    industrialise    absence    patient    sharp    ex    spin    first    attrition    ready    toulouse    models    fat    replace    hyposkin    model    pharmaceuticals    trials    save    sales    university    effect    sharpen    scientific    2017    reduces    plans    provides    issue    regulatory    health    customers    qualify    complete    local   

Project "HypoSkin" data sheet

The following table provides information about the project.

Coordinator
GENOSKIN SAS 

Organization address
address: CENTRE PIERRE POTIER, 1 PLACE PIERRE POTIER
city: TOULOUSE
postcode: 31100
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://www.genoskin.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-06-01   to  2018-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GENOSKIN SAS FR (TOULOUSE) coordinator 50˙000.00

Map

 Project objective

Subcutaneous injection drug market is highly increasing (CAGR of 7%) and is view as a viable alternative route for parenteral drug administration because it enables at-home injection, improves quality of life and reduces health care costs. However, the absence of accurate biological model to predict the effect of drug injection in the subcutaneous tissue limits their development. That issue leads to 88% of drug attrition causing a loss of more than €1B per developed drug and a sharp decrease of patient security during clinical trials.

HypoSkin is the first and unique in vitro standardized and ready-to-use testing kit containing living ex vivo human skin biopsies with subcutaneous fat, allowing pharmaceuticals to highly reliably predict local human’s response to the injection of a drug or a medical device. This disruptive innovation permits Hyposkin’s customers to save time and money (10 times faster and 5 times cheaper than animal experiment, confirmed in the on-going payed pilot test) as well as secure the development of their products before clinical trials. HypoSkin will become worldwide reference method to replace inadequate animal testing currently used today.

HypoSkin model is developed by Genoskin an innovative French company, founded in 2011 as a spin-off of the French National Center for Scientific Research and the Paul Sabatier University in Toulouse. Genoskin provides other human-skin alternative models to pharmaceuticals companies all over the world leading to sales of €700K in 2017.

The SME Instrument project will allow the company to improve, qualify and industrialise HypoSkin. To accomplish this goal Genoskin will complete a feasibility study to further analyse risks and cost of scale-up, the European regulatory framework and will deepen and sharpen the global subcutaneous injection market. Genoskin plans to lead the European and global alternative method market with an estimated turnover of € 34 M by 2024, and 110 new European and worldwide jobs.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HYPOSKIN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HYPOSKIN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

COPI (2020)

Carbon Offset Plug-in

Read More  

MealHero (2019)

Automated cooking for tasty and healthy meals in a convenient way

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More